Biochemistry

The statistical significance of distinctions amongst signal intensities was assessed by way of t student. AK inactivation by MK promotes Gadda transcriptional induction which drives a prominent arrest of Bcr Abl expressing cells in G M phase of cell cycle as well as the emergence of a polyploidy cell population MK induced the de phosphorylation from the p fusion protein at Y in Ba F cell lines stably transduced with Bcr Abl constructs coding to the wt or TI mutated protein and in K cell line...Read Full Story

Celgene Inc. and regulating agency Health Canada are informing the public about important new safety information that will be added to the warning and precautions for Thalomid (thalidomide capsules); this effort follows a detailed review of an ongoing clinical study. Thalomid is an immunomodulatory agent taken along with melphalan and prednisone by patients  65 and older who suffer from previously untreated multiple myeloma. Safety information was updated to include the following details...Read Full Story

Celgene Inc., in cooperation with Health Canada, has announced important new safety information concerning Thalomid that has been added to the drug’s product monograph. Health Canada, in a press release, describes Thalomid as an immunomodulatory agent indicated for the treatment of patients 65 years of age or older with previously untreated multiple myeloma, in combination with melphalan and prednisone (MPT). The updated safety information informs patients that “second primary malignancies...Read Full Story

Chronic myeloid leukemia savior-ponatinib Test drug ponatinib (Ariad Pharmaceuticals) for all other therapy ineffective chronic myeloid leukemia (CML) patients hope. Currently awaiting U.S. marketing approval. “For patients who previously received multiple treatments, we have never had such a high sustained response rate,” Houston University of Texas MD Anderson Cancer Center, Professor of leukemia Division Vice Jorges Cortes said. Dr. Cortes 54th American Society of Hematology annual meeting...Read Full Story

Ponatinib can Uniforms chronic myelogenous leukemia Atlanta – University of Texas MD Anderson Cancer Center, Dr. Jorge Cortes American Society of Hematology (ASH) annual meeting of the reported studies show that when other drugs for chronic myelogenous leukemia (CML) begins to fail when, Ponatinib but show a good effect. After strengthening the pre-treatment of relapsed or refractory chronic phase CML patients, investigational drugs Ponatinib make 56% of the patients had a major cytogenetic...Read Full Story